Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Andrew D WoodsNoah E BerlowMichael V OrtizFilemon Dela CruzArmaan SiddiqueeDiego F CoutinhoReshma PurohitKatherine E Tranbarger FreierJoel E MichalekMelvin LatharaKevin MatlockGanapati SrivivasaBrigitte Royer-PokoraRenata VeselskaAndrew L KungCharles KellerPublished in: Pediatric blood & cancer (2021)
We suggest that AZD5153, a novel dual-BRD4 inhibitor, can reduce MYCN levels in both anaplastic and nonanaplastic Wilms tumor cell lines, reduces tumor volume in Wilms tumor PDXs, and should be further explored for its therapeutic potential.
Keyphrases